Trends in Molecular Medicine
Volume 26, Issue 4, April 2020, Pages 352-354
SpotlightA lncRNA Decoy Predicts Sensitivity to Cisplatin
Section snippets
Acknowledgments
We thank the CERCA Programme/Generalitat de Catalunya and the Josep Carreras Foundation for institutional support.
References (9)
Noncoding RNAs in cancer therapy resistance and targeted drug development
J. Hematol. Oncol.
(2019)Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA
Cancer Cell
(2016)lncRNA CISAL inhibits BRCA1 transcription by forming a tertiary structure at its promoter
iScience
(2020)- et al.
The role of non-coding RNAs in oncology
Cell
(2019)
There are more references available in the full text version of this article.
Cited by (8)
Non-coding RNA-based therapeutics in cancer therapy: An emphasis on Wnt/β-catenin control
2023, European Journal of PharmacologyPrognostic value of mitochondrial CKMT2 in Pan-cancer and its tumor immune correlation analysis
2024, Scientific ReportsThe Involvement of Long Non-Coding RNAs in Glutamine-Metabolic Reprogramming and Therapeutic Resistance in Cancer
2022, International Journal of Molecular Sciences
- @
Twitter: @GroupGuil (S. Guil)
© 2020 Elsevier Ltd. All rights reserved.